Glaukos (NYSE:GKOS) Given “Buy” Rating at BTIG Research

Glaukos (NYSE:GKOS)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $131.00 target price on the medical instruments supplier’s stock. BTIG Research’s price objective would indicate a potential upside of 22.34% from the company’s previous close.

Several other brokerages also recently commented on GKOS. Stifel Nicolaus boosted their target price on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. Truist Financial boosted their price objective on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $135.00 price target on shares of Glaukos in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $133.69.

Glaukos Stock Performance

Glaukos stock opened at $107.08 on Wednesday. Glaukos has a 52-week low of $73.16 and a 52-week high of $161.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The stock has a fifty day moving average price of $114.66 and a two-hundred day moving average price of $98.34. The firm has a market capitalization of $6.15 billion, a P/E ratio of -69.53 and a beta of 0.70.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The firm had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The company’s revenue for the quarter was up 35.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.40) earnings per share. As a group, analysts anticipate that Glaukos will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Marc Stapley sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the transaction, the director directly owned 37,449 shares in the company, valued at $4,782,611.79. This represents a 28.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total transaction of $536,350.00. Following the completion of the transaction, the director directly owned 34,905 shares in the company, valued at approximately $3,744,259.35. The trade was a 12.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 310,315 shares of company stock worth $36,011,634. 6.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. UMB Bank n.a. boosted its position in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the last quarter. First Horizon Corp lifted its stake in Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 223 shares during the period. Los Angeles Capital Management LLC acquired a new position in Glaukos in the fourth quarter valued at about $28,000. Larson Financial Group LLC boosted its holdings in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 132 shares during the last quarter. Finally, REAP Financial Group LLC acquired a new position in shares of Glaukos during the 3rd quarter worth about $40,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record Q4 net sales of $143.1M, up ~36% year‑over‑year and above Street estimates — shows strong top‑line momentum in the business. Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Management reiterated a strong growth outlook on the earnings call and highlighted record sales, which supports the company’s long‑term revenue trajectory. Glaukos Corp (GKOS) Q4 2025 Earnings Call Highlights: Record Sales and Strong Growth Outlook
• Neutral Sentiment: Profitability is improving versus prior year (loss narrowed from $0.40 to $0.28 per share), but the company remains unprofitable on a GAAP basis. This is a mixed signal for investors balancing growth vs path to profits. Glaukos Q4 earnings / transcript
• Neutral Sentiment: Balance‑sheet metrics are healthy (high current and quick ratios, low debt‑to‑equity), giving the company runway to invest in growth even while profitable scale is pending. Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Reported EPS of ($0.28) missed the consensus ($0.22) by $0.06 — an earnings miss that often triggers near‑term selling despite the revenue beat. Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Company still posts negative net margin and negative return on equity; analysts expect continued FY losses (consensus roughly -$1.08), keeping valuation tethered to execution and margin improvement rather than near‑term earnings. Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.